SGLT2i

Effect of SGLT2 inhibition on aging-related biomarkers in older obese adults with pre-diabetes

*This study is now fully enrolled and no additional subjects are currently being recruited.

Purpose of this Study

The purpose of the research study is to evaluate whether older, obese adults with pre-diabetes can benefit from taking a drug called dapagliflozin (brand name FARXIGA) to reduce cellular damage, pro-inflammatory cells of aging, also called “senescent cells,” and other known markers of biological aging.

You may qualify if:

Age 60 and older
Borderline diabetes
Obese

You may NOT qualify if:

Live in a nursing home or assisted living facility.
Have diabetes
Have a chronic disabling disease
You are using medications for diabetes.

Duration of the Study

The study involves a total of 12 study visits over the course of approximately 4 to 5 months.

Study Procedures

Medical history
Physical examination/assessment
Blood tests
Body composition (DEXA)
Liver ultrasound and MRS/MRI
Muscle and fat sampling
Heart and lung exercise test & EKG (optional)

Study Location

UT Health San Antonio
Sam and Ann Barshop Institute for Longevity and Aging Studies
4939 Charles Katz Dr.
San Antonio, TX 78229

UT Health San Antonio Research Imaging Institute
8403 Floyd Curl Drive
San Antonio, TX 78229

UT San Antonio Medical Arts & Research Center
8300 Floyd Curl Drive
San Antonio, TX 78229

Compensation

Up to $470 is offered for the completion of this study.

Clinical Research Team

Principal Investigator:
Carolina Solis-Herrera, MD